Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343133 · ClinicalTrials.gov registry record · Phase 2
Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome
A Phase 2 study of Hematopoietic Syndrome Due to Acute Radiation Syndrome, sponsored by Neumedicines.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT02343133: Completed Phase 2 study of Hematopoietic Syndrome Due to Acute Radiation Syndrome, sponsored by Neumedicines.
NCT02343133 is a Phase 2 study of Hematopoietic Syndrome Due to Acute Radiation Syndrome that has completed, run by Neumedicines. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02343133, a Phase 2 study of Hematopoietic Syndrome Due to Acute Radiation Syndrome, has completed, sponsored by Neumedicines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine whether HemaMax is safe and well tolerated to support efficacy under FDA's Animal Rule to reduce the morbidity and mortality associated with the hematopoietic syndrome of acute radiation syndrome.
Primary Outcome
Number of subjects with adverse events as a measure of safety and tolerability
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL HemaMax
Study Locations (4)
Florida
- Covance Clinical Research Unit - Daytona Beach
Indiana
- Covance Clinical Research Unit - Evansville
Texas
- Covance Clinical Research Unit - Dallas
Wisconsin
- Covance Clinical Research Unit - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
What the finished NCT02343133 record still lists
NCT02343133 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Hematopoietic Syndrome Due to Acute Radiation Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02343133 reports a single indexed study location in Florida, Indiana, Texas.
Frequently Asked Questions
What is clinical trial NCT02343133 about?
NCT02343133 is a clinical study titled "Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome". The purpose of this study is to determine whether HemaMax is safe and well tolerated to support efficacy under FDA's Animal Rule to reduce the morbidity and mortality associated with the hematopoietic syndrome of acute radiation syndrome.
What is the current status of trial NCT02343133?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2015-01. Estimated completion is 2016-04.
What conditions does trial NCT02343133 study?
This clinical trial studies the following conditions: Hematopoietic Syndrome Due to Acute Radiation Syndrome.
What interventions are being tested in trial NCT02343133?
The interventions under investigation include: Placebo (DRUG), HemaMax (BIOLOGICAL).
Who is sponsoring clinical trial NCT02343133?
This trial is sponsored by Neumedicines, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02343133 being conducted?
This trial has 4 study locations across Florida, Indiana, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02343133's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia